Pfizer will buy NextWave Pharma for up to $700M

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

The approved NextWave's drug Quillivant XR in September, and the once-per-day drug is expected to be in pharmacies in January.

made a $20 million option payment to Cupertino, California-based NextWave in the second quarter to establish a merger agreement. The company will pay $255 million when the deal closes, and agreed to pay NextWave another $425 million based on sales milestones.

Pfizer said about 9.5 percent of children have received a diagnosis of ADHD at some point, and around 4 percent of adults have the condition.

NextWave is also developing extended release chewable tablets using the same drug. It has an advanced-stage study of the tablets in process, and aims to submit the product for approval next year.

Pfizer expects the deal to close during the fourth quarter, subject to regulatory approval.

Shares of . slipped a penny to $25.75 in premarket trading.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pfizer drug found with serious side effect

Nov 01, 2006

U.S. pharmaceutical company Pfizer Inc. says clinical trials of its heart medication torcetrapib suggest the drug has a potentially serious side effect.

AT&T goes on spectrum shopping binge

Aug 02, 2012

(AP) — AT&T Inc. has gone on a shopping spree for wireless spectrum, striking three separate deals that should let it increase its capacity for wireless broadband.

Pfizer will buy King Pharmaceuticals for $3.6B

Oct 12, 2010

(AP) -- Pfizer Inc. said Tuesday it will buy a company specializing in pain drugs in a $3.6 billion deal meant to shore up the portfolio of the world's largest drug company.

Citing liver damage, Pfizer withdraws Thelin

Dec 10, 2010

(AP) -- Pfizer Inc. said Friday it is pulling its blood pressure drug Thelin off the market and stopping all clinical trials because the drug can cause fatal liver damage.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

9 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments